Cubist Systematic Strategies, LLC Biogen Inc. Call Options Transaction History

Cubist Systematic Strategies, LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$189.07 - $236.8 $264,698 - $331,520	1,400 Added 43.75%	4,600 $891,000
Q2 2024 Aug 14, 2024	SELL	$190.52 - $236.72 $685,872 - $852,192	-3,600 Reduced 52.94%	3,200 $741,000
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $805,676 - $1.02 Million	3,800 Added 126.67%	6,800 $1.47 Million
Q4 2023 Feb 14, 2024	BUY	$222.59 - $267.94 $422,921 - $509,086	1,900 Added 172.73%	3,000 $776,000
Q3 2023 Nov 14, 2023	BUY	$253.3 - $285.89 $278,630 - $314,479	1,100 New	1,100 $282,000
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $1.1 Million - $1.26 Million	4,300 New	4,300 $1.2 Million

1,037

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.